Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a 16-day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
| |
| 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ketorolac | Drug | Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day. Placebo |
|
| Measure | Description | Time Frame |
|---|---|---|
| Resolution of Post Operative Inflammation | Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) | Day 14 |
| Measure | Description | Time Frame |
|---|---|---|
| Ocular Pain | Measured on a scale of 0-4 (0 = none, 4 = intolerable) | Day 1 |
| Mean Pupil Area | Pupil area post-irrigation and aspiration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Artesia | California | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21145532 | Derived | Donnenfeld ED, Nichamin LD, Hardten DR, Raizman MB, Trattler W, Rajpal RK, Alpern LM, Felix C, Bradford RR, Villanueva L, Hollander DA, Schiffman RM. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol. 2011 Mar;151(3):420-6.e1. doi: 10.1016/j.ajo.2010.09.003. Epub 2010 Dec 9. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ketorolac Solution | |
| FG001 | Vehicle Solution |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ketorolac Solution | |
| BG001 | Vehicle Solution | |
| BG002 | Total |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Resolution of Post Operative Inflammation | Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) | Modified Intent-to-Treat Population | Posted | Number | % of participants with a score of 0 | Day 14 |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ketorolac Solution |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina Unstable | Cardiac disorders | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Foreign body sensation in eyes | Eye disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Therapeutic Area Head | Allergan, Inc. | (714)246-4500 | clinicaltrials@allergan.com |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D020910 | Ketorolac |
| ID | Term |
|---|---|
| D007213 | Indomethacin |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 0 |
Total of all reporting groups
| participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
|
| Secondary | Ocular Pain | Measured on a scale of 0-4 (0 = none, 4 = intolerable) | Modified Intent-to-Treat Population | Posted | Number | % of participants with a score of 0 | Day 1 |
|
|
|
| Secondary | Mean Pupil Area | Pupil area post-irrigation and aspiration | Modified Intent-to-Treat Population | Posted | Mean | Standard Deviation | millimeters squared (mm²) | Day 0 |
|
|
|
| Post-Hoc | Visual Acuity | Patients with ≥ 3 line improvement in visual acuity | Modified Intent-to-Treat Population | Posted | Number | Percentage of patients with ≥ 3 lines | Change from baseline at Day 14 |
|
|
|
| 2 |
| 46 |
| EG001 | Vehicle Solution | 1 | 52 |
| Cardiac Arrest | Cardiac disorders | Non-systematic Assessment |
|
| Coronary Artery Occlusion | Cardiac disorders | Non-systematic Assessment |
|
| Coronary Artery Disease | Cardiac disorders | Non-systematic Assessment |
|
| Iritis | Eye disorders | Systematic Assessment |
|
| Eye Pain | Eye disorders | Non-systematic Assessment |
|
| Conjunctival Hyperemia | Eye disorders | Systematic Assessment |
|
| Photophobia | Eye disorders | Non-systematic Assessment |
|
| Headache | Nervous system disorders | Non-systematic Assessment |
|
| Intraocular Pressure Increased | Eye disorders | Systematic Assessment |
|
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
| D006571 | Heterocyclic Compounds |